[S02DA03, antipyrine, The serum concentration of Antipyrine can be increased when it is combined with Imatinib.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Streptokinase is combined with Imatinib.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Imatinib.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Imatinib.]
[L04AA27, fingolimod, Imatinib may increase the immunosuppressive activities of Fingolimod.]
[J01EC02, sulfadiazine, The metabolism of Imatinib can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Imatinib can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Imatinib.]
[J01EC03, sulfamoxole, The metabolism of Imatinib can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Imatinib can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Imatinib can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Imatinib.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Imatinib is combined with Sulpiride.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Imatinib.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Imatinib is combined with Mercaptopurine.]
[N06DA01, tacrine, The metabolism of Imatinib can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The serum concentration of Tamoxifen can be increased when it is combined with Imatinib.]
[L01CB02, teniposide, The serum concentration of Teniposide can be increased when it is combined with Imatinib.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Imatinib.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Imatinib.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Imatinib.]
[N07XX06, tetrabenazine, The serum concentration of Tetrabenazine can be increased when it is combined with Imatinib.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Imatinib.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Imatinib.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Imatinib.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Imatinib is combined with Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Imatinib.]
[R03DA04, theophylline, The serum concentration of Theophylline can be increased when it is combined with Imatinib.]
[P02CA02, thiabendazole, The metabolism of Imatinib can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Imatinib is combined with Eribulin.]
[L01AC01, thiotepa, The serum concentration of Thiotepa can be increased when it is combined with Imatinib.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Imatinib.]
[N05CA19, thiopental, The metabolism of Imatinib can be decreased when combined with Thiopental.]
[N05AC02, thioridazine, The serum concentration of Thioridazine can be increased when it is combined with Imatinib.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Imatinib.]
[C01BB04, aprindine, The serum concentration of Aprindine can be increased when it is combined with Imatinib.]
[V04CJ01, thyrotropin, The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Imatinib.]
[V04CJ02, thyrotropin-releasing hormone, The therapeutic efficacy of Protirelin can be decreased when used in combination with Imatinib.]
[B01AC05, ticlopidine, The serum concentration of Ticlopidine can be increased when it is combined with Imatinib.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Imatinib.]
[P01AB02, tinidazole, Imatinib may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Imatinib.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Imatinib.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Imatinib.]
[N06AF04, tranylcypromine, The metabolism of Imatinib can be decreased when combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Trapidil is combined with Imatinib.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Imatinib.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Imatinib is combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Imatinib is combined with Triamcinolone.]
[C03DB02, triamterene, The metabolism of Imatinib can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The serum concentration of Triazolam can be increased when it is combined with Imatinib.]
[C03AA06, trichlormethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Imatinib.]
[N05AB06, trifluoperazine, The metabolism of Trifluoperazine can be decreased when combined with Imatinib.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Imatinib.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Imatinib is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Imatinib is combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Imatinib.]
[S01ED04, metipranolol, The serum concentration of Metipranolol can be increased when it is combined with Imatinib.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Imatinib.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Imatinib.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Imatinib.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Imatinib.]
[R06AC04, tripelennamine, The metabolism of Imatinib can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Imatinib.]
[J01FA08, troleandomycin, The serum concentration of Imatinib can be increased when it is combined with Troleandomycin.]
[N06AX24, vilazodone, The serum concentration of Vilazodone can be increased when it is combined with Imatinib.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Imatinib.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Belimumab.]
[L01EX04, vandetanib, The serum concentration of Vandetanib can be increased when it is combined with Imatinib.]
[L02BX03, abiraterone, The serum concentration of Imatinib can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Imatinib can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Imatinib can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Imatinib can be increased when it is combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Imatinib.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Urokinase is combined with Imatinib.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Imatinib is combined with Belatacept.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Imatinib.]
[B01AF01, rivaroxaban, Imatinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Imatinib.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Imatinib.]
[C08DA01, verapamil, The metabolism of Imatinib can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Imatinib can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Imatinib.]
[L01CA02, vincristine, The serum concentration of Vincristine can be increased when it is combined with Imatinib.]
[L01CA03, vindesine, The serum concentration of Vindesine can be increased when it is combined with Imatinib.]
[B03BA01, vitamin B12, The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Imatinib.]
[B01AA03, warfarin, Imatinib may increase the anticoagulant activities of Warfarin.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Imatinib.]
[N05AF05, zuclopenthixol, The serum concentration of Zuclopenthixol can be increased when it is combined with Imatinib.]
[J05AE02, indinavir, The serum concentration of Imatinib can be increased when it is combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Imatinib can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Imatinib.]
[L01ED01, crizotinib, The serum concentration of Crizotinib can be increased when it is combined with Imatinib.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Imatinib.]
[R03DC01, zafirlukast, The metabolism of Imatinib can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Imatinib.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Trovafloxacin.]
[L01XX02, asparaginase, The risk or severity of liver damage can be increased when Asparaginase Escherichia coli is combined with Imatinib.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Imatinib.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Imatinib.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be decreased when combined with Imatinib.]
[L01EJ01, ruxolitinib, The serum concentration of Ruxolitinib can be increased when it is combined with Imatinib.]
[G04BD07, tolterodine, The serum concentration of Tolterodine can be increased when it is combined with Imatinib.]
[C07AB03, atenolol, The serum concentration of Atenolol can be increased when it is combined with Imatinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Imatinib.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Imatinib.]
[J02AC03, voriconazole, The serum concentration of Imatinib can be increased when it is combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Imatinib.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Imatinib.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Imatinib.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Imatinib.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Imatinib is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Imatinib.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Imatinib is combined with Azacitidine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Imatinib is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Imatinib.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Imatinib.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Imatinib.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Imatinib.]
[L01FD02, pertuzumab, The risk or severity of cardiotoxicity can be increased when Imatinib is combined with Pertuzumab.]
[A08AA11, lorcaserin, The serum concentration of Lorcaserin can be increased when it is combined with Imatinib.]
[G04BD12, mirabegron, The serum concentration of Imatinib can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Imatinib is combined with Carfilzomib.]
[V03AX03, cobicistat, The serum concentration of Imatinib can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The serum concentration of Imatinib can be increased when it is combined with Elvitegravir.]
[L02BB04, enzalutamide, The metabolism of Imatinib can be increased when combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Imatinib.]
[L04AA31, teriflunomide, The serum concentration of Imatinib can be decreased when it is combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Defibrotide is combined with Imatinib.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Imatinib is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Imatinib is combined with Aldosterone.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Imatinib.]
[N05CA04, barbital, The metabolism of Barbital can be decreased when combined with Imatinib.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may decrease the cardiotoxic activities of Imatinib.]
[J05AE04, nelfinavir, The serum concentration of Imatinib can be increased when it is combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Imatinib is combined with Bendamustine.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be decreased when combined with Imatinib.]
[C08CA13, lercanidipine, The metabolism of Lercanidipine can be decreased when combined with Imatinib.]
[N06DA02, donepezil, The serum concentration of Donepezil can be increased when it is combined with Imatinib.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Imatinib.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Imatinib.]
[N02CC03, zolmitriptan, The metabolism of Imatinib can be decreased when combined with Zolmitriptan.]
[G04BD10, darifenacin, The serum concentration of Darifenacin can be increased when it is combined with Imatinib.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Imatinib.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Imatinib.]
[G04BE03, sildenafil, The serum concentration of Sildenafil can be increased when it is combined with Imatinib.]
[L01EA05, ponatinib, The serum concentration of Ponatinib can be increased when it is combined with Imatinib.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Imatinib.]
[C10AX12, lomitapide, The serum concentration of Lomitapide can be increased when it is combined with Imatinib.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Imatinib.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Imatinib.]
[A10BH04, alogliptin, The serum concentration of Alogliptin can be increased when it is combined with Imatinib.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Imatinib can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Imatinib.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Imatinib.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Imatinib.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Imatinib is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Imatinib.]
[M04AB03, benzbromarone, Imatinib may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Imatinib.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Imatinib.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Imatinib.]
[R02AD01, benzocaine, The serum concentration of Benzocaine can be increased when it is combined with Imatinib.]
[M01AH01, celecoxib, The serum concentration of Celecoxib can be increased when it is combined with Imatinib.]
[L04AA18, everolimus, The serum concentration of Everolimus can be increased when it is combined with Imatinib.]
[N04AC01, benztropine, The serum concentration of Benzatropine can be increased when it is combined with Imatinib.]
[L01EC02, dabrafenib, The serum concentration of Imatinib can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Imatinib can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The serum concentration of Benzyl alcohol can be increased when it is combined with Imatinib.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Imatinib.]
[L01EB03, afatinib, Imatinib may decrease the excretion rate of Afatinib which could result in a higher serum level.]
[N06AX28, levomilnacipran, The serum concentration of Levomilnacipran can be increased when it is combined with Imatinib.]
[J05AJ03, dolutegravir, Imatinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.]
[C08EA02, bepridil, The serum concentration of Bepridil can be increased when it is combined with Imatinib.]
[C02KX05, riociguat, Imatinib may decrease the excretion rate of Riociguat which could result in a higher serum level.]
[L03AA14, lipegfilgrastim, Imatinib may increase the myelosuppressive activities of Lipegfilgrastim.]
[A05AA03, cholic acid, Cholic Acid may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Imatinib.]
[N06AX26, vortioxetine, The serum concentration of Vortioxetine can be increased when it is combined with Imatinib.]
[N03AF04, eslicarbazepine, The metabolism of Imatinib can be decreased when combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Imatinib can be increased when it is combined with Luliconazole.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[J05AP08, sofosbuvir, Imatinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The serum concentration of Dapagliflozin can be increased when it is combined with Imatinib.]
[C07AB04, acebutolol, The serum concentration of Acebutolol can be increased when it is combined with Imatinib.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Imatinib.]
[A16AA07, metreleptin, The metabolism of Imatinib can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Imatinib can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Imatinib.]
[S01ED02, betaxolol, The serum concentration of Betaxolol can be increased when it is combined with Imatinib.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Argatroban is combined with Imatinib.]
[C10AB02, bezafibrate, The metabolism of Imatinib can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Imatinib can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Imatinib.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Imatinib.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Vedolizumab.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Imatinib.]
[B01AA07, acenocoumarol, Imatinib may increase the anticoagulant activities of Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Imatinib is combined with Belinostat.]
[L01EM01, idelalisib, The serum concentration of Idelalisib can be increased when it is combined with Imatinib.]
[N07XX08, tafamidis, The serum concentration of Imatinib can be increased when it is combined with Tafamidis.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Imatinib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Imatinib is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Imatinib.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Imatinib.]
[J01XA05, oritavancin, The metabolism of Imatinib can be decreased when combined with Oritavancin.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Imatinib is combined with Decitabine.]
[N04AA02, biperiden, The metabolism of Imatinib can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The serum concentration of Pirfenidone can be increased when it is combined with Imatinib.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Imatinib.]
[S03AA06, gentamicin, The serum concentration of Gentamicin can be increased when it is combined with Imatinib.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Imatinib is combined with Blinatumomab.]
[J05AP09, dasabuvir, The serum concentration of Dasabuvir can be increased when it is combined with Imatinib.]
[L01XK01, olaparib, The serum concentration of Olaparib can be increased when it is combined with Imatinib.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Imatinib.]
[B01AF03, edoxaban, The risk or severity of bleeding can be increased when Edoxaban is combined with Imatinib.]
[N06AX11, mirtazapine, The serum concentration of Mirtazapine can be increased when it is combined with Imatinib.]
[L04AC10, secukinumab, The metabolism of Imatinib can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Palbociclib can be increased when it is combined with Imatinib.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Imatinib.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Imatinib.]
[J05AP07, daclatasvir, Daclatasvir may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Imatinib.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Imatinib.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Tioclomarol is combined with Imatinib.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Ivabradine.]
[J05AP06, asunaprevir, The serum concentration of Asunaprevir can be increased when it is combined with Imatinib.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Cangrelor is combined with Imatinib.]
[N05AX16, brexpiprazole, The serum concentration of Brexpiprazole can be increased when it is combined with Imatinib.]
[L01XJ02, sonidegib, The serum concentration of Sonidegib can be increased when it is combined with Imatinib.]
[A04AD14, rolapitant, The metabolism of Imatinib can be decreased when combined with Rolapitant.]
[A02BC03, lansoprazole, Lansoprazole may increase the dermatologic adverse activities of Imatinib.]
[L01CX01, trabectedin, The serum concentration of Trabectedin can be increased when it is combined with Imatinib.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Imatinib can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Imatinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Imatinib.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be increased when it is combined with Imatinib.]
[L01XG03, ixazomib, The serum concentration of Ixazomib can be increased when it is combined with Imatinib.]
[L01ED03, alectinib, The serum concentration of Alectinib can be increased when it is combined with Imatinib.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Imatinib.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Imatinib.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Imatinib.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Imatinib.]
[J05AP10, elbasvir, Elbasvir may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[J05AP11, grazoprevir, Grazoprevir may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Imatinib.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Ixekizumab.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Imatinib.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Imatinib.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Imatinib.]
[C08CA01, amlodipine, The serum concentration of Amlodipine can be increased when it is combined with Imatinib.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Imatinib.]
[A05AA04, obeticholic acid, The metabolism of Imatinib can be decreased when combined with Obeticholic acid.]
[S01ED03, levobunolol, The serum concentration of Levobunolol can be increased when it is combined with Imatinib.]
[N01BB01, bupivacaine, The serum concentration of Bupivacaine can be increased when it is combined with Imatinib.]
[C07AA19, bupranolol, The serum concentration of Bupranolol can be increased when it is combined with Imatinib.]
[N07BC01, buprenorphine, The serum concentration of Buprenorphine can be increased when it is combined with Imatinib.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Imatinib.]
[N05BE01, buspirone, The serum concentration of Buspirone can be increased when it is combined with Imatinib.]
[L01AB01, busulfan, The serum concentration of Busulfan can be increased when it is combined with Imatinib.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Imatinib is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Imatinib.]
[S01GX07, azelastine, The serum concentration of Azelastine can be increased when it is combined with Imatinib.]
[L01XK03, rucaparib, The serum concentration of Rucaparib can be increased when it is combined with Imatinib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Imatinib.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Brodalumab.]
[L01EF02, ribociclib, The serum concentration of Imatinib can be increased when it is combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Imatinib.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Ocrelizumab.]
[N07XX16, deutetrabenazine, The serum concentration of Deutetrabenazine can be increased when it is combined with Imatinib.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Imatinib.]
[N06BC01, caffeine, The metabolism of Imatinib can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Imatinib.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Imatinib.]
[J05AE09, tipranavir, The serum concentration of Imatinib can be increased when it is combined with Tipranavir.]
[H03BA03, benzylthiouracil, The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Imatinib.]
[N07XX13, valbenazine, The serum concentration of Valbenazine can be increased when it is combined with Imatinib.]
[L04AB02, infliximab, The metabolism of Imatinib can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Imatinib can be increased when combined with Midostaurin.]
[H05AA04, abaloparatide, The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Imatinib.]
[L01ED04, brigatinib, The serum concentration of Brigatinib can be increased when it is combined with Imatinib.]
[N04BD03, safinamide, Safinamide may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Imatinib.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Imatinib.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Guselkumab.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Imatinib.]
[L01XX59, enasidenib, The serum concentration of Enasidenib can be increased when it is combined with Imatinib.]
[L01EH02, neratinib, The serum concentration of Neratinib can be increased when it is combined with Imatinib.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Imatinib is combined with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Imatinib.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Imatinib.]
[J05AG03, efavirenz, The serum concentration of Imatinib can be increased when it is combined with Efavirenz.]
[C07AA17, bopindolol, The serum concentration of Bopindolol can be increased when it is combined with Imatinib.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Imatinib.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Imatinib.]
[V03AF08, palifermin, The therapeutic efficacy of Palifermin can be decreased when used in combination with Imatinib.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Imatinib is combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Buflomedil is combined with Imatinib.]
[L01EL02, acalabrutinib, The serum concentration of Acalabrutinib can be increased when it is combined with Imatinib.]
[J05AX18, letermovir, The serum concentration of Letermovir can be increased when it is combined with Imatinib.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Imatinib.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Imatinib.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Capsaicin.]
[A10BK04, ertugliflozin, Imatinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Imatinib.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Imatinib can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Imatinib can be increased when combined with Carbamazepine.]
[H03BB01, carbimazole, The therapeutic efficacy of Carbimazole can be decreased when used in combination with Imatinib.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Imatinib.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Imatinib.]
[C07AG02, carvedilol, The serum concentration of Carvedilol can be increased when it is combined with Imatinib.]
[B02BX09, fostamatinib, Fostamatinib may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Imatinib.]
[B02BX08, avatrombopag, Avatrombopag may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Baricitinib.]
[L01EC03, encorafenib, The serum concentration of Encorafenib can be increased when it is combined with Imatinib.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Imatinib.]
[C07AB08, celiprolol, The serum concentration of Celiprolol can be increased when it is combined with Imatinib.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Imatinib.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Ivosidenib.]
[P01BA07, tafenoquine, The serum concentration of Tafenoquine can be increased when it is combined with Imatinib.]
[N03AX17, stiripentol, The serum concentration of Imatinib can be increased when it is combined with Stiripentol.]
[B02BX07, lusutrombopag, Imatinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.]
[J05AX24, tecovirimat, The metabolism of Imatinib can be decreased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Imatinib.]
[L01EM04, duvelisib, Imatinib may decrease the excretion rate of Duvelisib which could result in a higher serum level.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Imatinib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Imatinib.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Imatinib.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Chloroprocaine.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Imatinib.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Imatinib.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Imatinib.]
[L01XK04, talazoparib, Imatinib may decrease the excretion rate of Talazoparib which could result in a higher serum level.]
[M03BA02, carisoprodol, The metabolism of Imatinib can be decreased when combined with Carisoprodol.]
[R03BB08, revefenacin, The serum concentration of Revefenacin can be increased when it is combined with Imatinib.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Imatinib.]
[L04AA39, emapalumab, The metabolism of Imatinib can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Imatinib.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Imatinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Imatinib.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Ravulizumab.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Imatinib.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Imatinib.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Caplacizumab is combined with Imatinib.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Imatinib.]
[S01ED05, carteolol, The serum concentration of Carteolol can be increased when it is combined with Imatinib.]
[P02BX04, triclabendazole, The metabolism of Imatinib can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Imatinib.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Imatinib is combined with Siponimod.]
[J01FA09, clarithromycin, The serum concentration of Imatinib can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, The serum concentration of Solriamfetol can be increased when it is combined with Imatinib.]
[L01EN01, erdafitinib, The serum concentration of Erdafitinib can be increased when it is combined with Imatinib.]
[N05BA09, clobazam, The metabolism of Imatinib can be decreased when combined with Clobazam.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Imatinib is combined with Cloprednol.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Imatinib.]
[L04AB01, etanercept, The metabolism of Imatinib can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Imatinib is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Risankizumab.]
[L01EM03, alpelisib, The serum concentration of Alpelisib can be increased when it is combined with Imatinib.]
[J01DC04, cefaclor, Imatinib may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[L02BB06, darolutamide, The serum concentration of Imatinib can be increased when it is combined with Darolutamide.]
[L01EX15, pexidartinib, The serum concentration of Pexidartinib can be increased when it is combined with Imatinib.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Imatinib.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be decreased when combined with Imatinib.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Upadacitinib.]
[L01EJ02, fedratinib, Fedratinib may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Imatinib can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Imatinib.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Imatinib.]
[N04CX01, istradefylline, The serum concentration of Istradefylline can be increased when it is combined with Imatinib.]
[C03AA09, cyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Imatinib.]
[G04BE04, yohimbine, The serum concentration of Yohimbine can be increased when it is combined with Imatinib.]
[A10AE03, insulin, regular, pork, The metabolism of Imatinib can be increased when combined with Insulin pork.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Imatinib.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Imatinib is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Imatinib.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Imatinib.]
[N02CC08, lasmiditan, The serum concentration of Imatinib can be increased when it is combined with Lasmiditan.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Imatinib is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The serum concentration of Zanubrutinib can be increased when it is combined with Imatinib.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Imatinib.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Imatinib.]
[N03AX25, cenobamate, The serum concentration of Imatinib can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Imatinib can be increased when it is combined with Givosiran.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Imatinib.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Imatinib.]
[R06AB02, dexchlorpheniramine, The serum concentration of Dexchlorpheniramine can be increased when it is combined with Imatinib.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Imatinib.]
[N05CM21, lemborexant, The metabolism of Lemborexant can be decreased when combined with Imatinib.]
[L01XX72, tazemetostat, Imatinib may decrease the excretion rate of Tazemetostat which could result in a higher serum level.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Teprotumumab.]
[M01AX21, diacetylrhein, The metabolism of Imatinib can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Imatinib.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Imatinib.]
[H02CA02, osilodrostat, The metabolism of Imatinib can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The serum concentration of Imatinib can be increased when it is combined with Amprenavir.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be decreased when combined with Imatinib.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Imatinib.]
[L04AA38, ozanimod, Imatinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Imatinib.]
[N02AA08, dihydrocodeine, The serum concentration of Dihydrocodeine can be increased when it is combined with Imatinib.]
[N02CC06, eletriptan, The serum concentration of Eletriptan can be increased when it is combined with Imatinib.]
[M01AH02, rofecoxib, The metabolism of Imatinib can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Imatinib.]
[C08CA16, clevidipine, The serum concentration of Clevidipine can be increased when it is combined with Imatinib.]
[C01BD07, dronedarone, Imatinib may increase the QTc-prolonging activities of Dronedarone.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Imatinib.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Imatinib.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Imatinib.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Imatinib.]
[L01EX17, capmatinib, The serum concentration of Imatinib can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Imatinib is combined with Fluprednidene.]
[G04BD09, trospium, The metabolism of Imatinib can be decreased when combined with Trospium.]
[L01EX19, ripretinib, Imatinib may decrease the excretion rate of Ripretinib which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Imatinib can be increased when it is combined with Selpercatinib.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Lepirudin is combined with Imatinib.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Imatinib is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Imatinib is combined with Stepronin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Imatinib.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Imatinib.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Imatinib.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Imatinib.]
[L01FX15, belantamab mafodotin, Imatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Imatinib can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be increased when it is combined with Imatinib.]
[P01BA01, chloroquine, The serum concentration of Chloroquine can be increased when it is combined with Imatinib.]
[L01EX23, pralsetinib, Pralsetinib may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[C03AA04, chlorothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Imatinib.]
[R06AB04, chlorpheniramine, The serum concentration of Chlorpheniramine can be increased when it is combined with Imatinib.]
[N05AA01, chlorpromazine, The serum concentration of Chlorpromazine can be increased when it is combined with Imatinib.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Imatinib.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Imatinib.]
[M03BB03, chlorzoxazone, The serum concentration of Chlorzoxazone can be increased when it is combined with Imatinib.]
[A11CC05, cholecalciferol, The metabolism of Imatinib can be decreased when combined with Cholecalciferol.]
[N02BA03, choline salicylate, The serum concentration of Choline salicylate can be increased when it is combined with Imatinib.]
[M01AB08, etodolac, The metabolism of Etodolac can be decreased when combined with Imatinib.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Imatinib.]
[A16AX20, lonafarnib, The serum concentration of Lonafarnib can be increased when it is combined with Imatinib.]
[L01BB05, fludarabine, The therapeutic efficacy of Fludarabine can be decreased when used in combination with Imatinib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Imatinib.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Imatinib is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Imatinib can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Imatinib can be decreased when combined with Tepotinib.]
[V03AF12, trilaciclib, Imatinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Imatinib.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Imatinib.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Imatinib.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Imatinib.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Imatinib.]
[S01JA01, fluorescein, Imatinib may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[R03CC15, formoterol, The serum concentration of Formoterol can be increased when it is combined with Imatinib.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Imatinib.]
[S01LA08, bevacizumab, The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Imatinib.]
[L01EK03, tivozanib, Tivozanib may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Imatinib can be increased when it is combined with Peginterferon alfa-2b.]
[G03GA06, follitropin beta, The therapeutic efficacy of Follitropin can be decreased when used in combination with Imatinib.]
[A02BA01, cimetidine, The metabolism of Imatinib can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The serum concentration of Cinnarizine can be increased when it is combined with Imatinib.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Imatinib.]
[L01XX73, sotorasib, The serum concentration of Imatinib can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Imatinib.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Imatinib.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Imatinib.]
[N06AB04, citalopram, The serum concentration of Citalopram can be increased when it is combined with Imatinib.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Imatinib is combined with Pegcetacoplan.]
[H01AC07, somapacitan, The metabolism of Imatinib can be decreased when combined with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Imatinib.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Imatinib is combined with Belumosudil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Imatinib is combined with Fexinidazole.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Anifrolumab.]
[L01XX74, belzutifan, The metabolism of Belzutifan can be decreased when combined with Imatinib.]
[H01AC09, lonapegsomatropin, The metabolism of Imatinib can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Imatinib.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Imatinib.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Imatinib.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Imatinib.]
[N06AX25, St. John's wort extract, The metabolism of Imatinib can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Imatinib can be decreased when combined with Asciminib.]
[J05AX10, maribavir, Maribavir may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Imatinib is combined with Ropeginterferon alfa-2b.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Imatinib.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Imatinib.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Tenecteplase is combined with Imatinib.]
[B06AX04, mitapivat, The metabolism of Imatinib can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Imatinib can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The serum concentration of Clomipramine can be increased when it is combined with Imatinib.]
[S01EA04, clonidine, The serum concentration of Clonidine can be increased when it is combined with Imatinib.]
[C01EB24, mavacamten, The serum concentration of Imatinib can be decreased when it is combined with Mavacamten.]
[J02AC06, oteseconazole, The serum concentration of Imatinib can be increased when it is combined with Oteseconazole.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Imatinib.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Imatinib is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Deucravacitinib.]
[A05BA08, glycyrrhizic acid, Imatinib may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[H01CC04, linzagolix, The serum concentration of Imatinib can be increased when it is combined with Linzagolix.]
[A04AA01, ondansetron, The serum concentration of Ondansetron can be increased when it is combined with Imatinib.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Imatinib.]
[N05AH02, clozapine, The serum concentration of Clozapine can be increased when it is combined with Imatinib.]
[A10BK06, sotagliflozin, Sotagliflozin may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[H01AC08, somatrogon, The metabolism of Imatinib can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Imatinib can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The serum concentration of Codeine can be increased when it is combined with Imatinib.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Imatinib.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Imatinib is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Imatinib.]
[A10BX03, nateglinide, The serum concentration of Nateglinide can be increased when it is combined with Imatinib.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Imatinib is combined with Nelarabine.]
[J01FA15, telithromycin, The serum concentration of Imatinib can be increased when it is combined with Telithromycin.]
[R03BA08, ciclesonide, The serum concentration of Ciclesonide can be increased when it is combined with Imatinib.]
[B01AC10, indobufen, The risk or severity of bleeding can be increased when Indobufen is combined with Imatinib.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Imatinib.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Imatinib.]
[C01AA06, lanatoside C, Lanatoside C may decrease the cardiotoxic activities of Imatinib.]
[N02CC05, almotriptan, The serum concentration of Almotriptan can be increased when it is combined with Imatinib.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Imatinib.]
[J02AC02, itraconazole, The serum concentration of Imatinib can be increased when it is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Bemiparin is combined with Imatinib.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Imatinib.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Imatinib.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Imatinib is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The serum concentration of Fusidic acid can be increased when it is combined with Imatinib.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Imatinib.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Imatinib.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Imatinib.]
[J02AC04, posaconazole, The serum concentration of Imatinib can be increased when it is combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Imatinib can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Imatinib.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Imatinib.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Imatinib.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Imatinib.]
[S01BA03, cortisone, The metabolism of Imatinib can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The serum concentration of Lofexidine can be increased when it is combined with Imatinib.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Imatinib.]
[R06AX13, loratadine, The metabolism of Imatinib can be decreased when combined with Loratadine.]
[C08CA11, manidipine, The metabolism of Imatinib can be decreased when combined with Manidipine.]
[C07AA14, mepindolol, The serum concentration of Mepindolol can be increased when it is combined with Imatinib.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Imatinib is combined with Meprednisone.]
[R06AD07, mequitazine, The serum concentration of Mequitazine can be increased when it is combined with Imatinib.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Imatinib.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Imatinib.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be decreased when combined with Imatinib.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Imatinib.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Imatinib.]
[C03AA07, cyclopenthiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Imatinib.]
[L01AA01, cyclophosphamide, The serum concentration of Cyclophosphamide can be increased when it is combined with Imatinib.]
[N06AX07, minaprine, The serum concentration of Minaprine can be increased when it is combined with Imatinib.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Imatinib.]
[N06AG02, moclobemide, The serum concentration of Moclobemide can be increased when it is combined with Imatinib.]
[N06BA07, modafinil, The metabolism of Imatinib can be decreased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Imatinib.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Imatinib.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Imatinib.]
[C03XA02, conivaptan, The serum concentration of Imatinib can be increased when it is combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Imatinib is combined with Cytarabine.]
[J05AF10, entecavir, The metabolism of Imatinib can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Imatinib.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Imatinib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Imatinib is combined with Dacarbazine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Imatinib is combined with Dactinomycin.]
[G03XA01, danazol, The serum concentration of Imatinib can be increased when it is combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Imatinib.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Imatinib is combined with Daunorubicin.]
[C02CC04, debrisoquin, The serum concentration of Debrisoquine can be increased when it is combined with Imatinib.]
[A04AD11, nabilone, The metabolism of Imatinib can be decreased when combined with Nabilone.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Imatinib.]
[C07AB12, nebivolol, The serum concentration of Nebivolol can be increased when it is combined with Imatinib.]
[N06AX06, nefazodone, The serum concentration of Imatinib can be increased when it is combined with Nefazodone.]
[L02BB02, nilutamide, The metabolism of Imatinib can be decreased when combined with Nilutamide.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Imatinib.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Fondaparinux is combined with Imatinib.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Imatinib.]
[N06AB10, escitalopram, The serum concentration of Imatinib can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The serum concentration of Solifenacin can be increased when it is combined with Imatinib.]
[N06AA01, desipramine, The serum concentration of Desipramine can be increased when it is combined with Imatinib.]
[C01AA07, deslanoside, Deslanoside may decrease the cardiotoxic activities of Imatinib.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Imatinib.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Imatinib.]
[N03AF02, oxcarbazepine, The metabolism of Imatinib can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Imatinib can be increased when combined with Dexamethasone.]
[G04BD04, oxybutynin, The metabolism of Imatinib can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The serum concentration of Dexfenfluramine can be increased when it is combined with Imatinib.]
[L04AB04, adalimumab, The metabolism of Imatinib can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The serum concentration of Gefitinib can be increased when it is combined with Imatinib.]
[N06BA02, dextroamphetamine, The serum concentration of Amphetamine can be increased when it is combined with Imatinib.]
[R05DA09, dextromethorphan, The serum concentration of Dextromethorphan can be increased when it is combined with Imatinib.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Imatinib.]
[H05AA02, teriparatide, The therapeutic efficacy of Teriparatide can be decreased when used in combination with Imatinib.]
[N06AB05, paroxetine, The serum concentration of Paroxetine can be increased when it is combined with Imatinib.]
[B01AC04, clopidogrel, The metabolism of Imatinib can be decreased when combined with Clopidogrel.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Imatinib.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Imatinib.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Imatinib.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Imatinib.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Imatinib.]
[A10BG03, pioglitazone, The metabolism of Imatinib can be decreased when combined with Pioglitazone.]
[L01DC04, ixabepilone, The serum concentration of Ixabepilone can be increased when it is combined with Imatinib.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be increased when it is combined with Imatinib.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Imatinib is combined with Pirarubicin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[C08CA03, isradipine, The serum concentration of Isradipine can be increased when it is combined with Imatinib.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Imatinib is combined with Difluocortolone.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Imatinib.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Imatinib.]
[C02DB01, dihydralazine, The metabolism of Imatinib can be decreased when combined with Dihydralazine.]
[C10AX09, ezetimibe, Imatinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[L01XX24, pegaspargase, The risk or severity of liver damage can be increased when Pegaspargase is combined with Imatinib.]
[C04AE04, dihydroergocristine, Imatinib may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, The serum concentration of Dihydroergotamine can be increased when it is combined with Imatinib.]
[N02AA03, hydromorphone, The metabolism of Hydromorphone can be decreased when combined with Imatinib.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Imatinib.]
[J05AE08, atazanavir, The serum concentration of Imatinib can be increased when it is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Imatinib.]
[H03BC01, potassium perchlorate, The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Imatinib.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Pramocaine.]
[C08DB01, diltiazem, The serum concentration of Diltiazem can be increased when it is combined with Imatinib.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Imatinib.]
[M02AX03, dimethyl sulfoxide, The metabolism of Imatinib can be decreased when combined with Dimethyl sulfoxide.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Imatinib.]
[G02AD02, dinoprostone, The risk or severity of adverse effects can be increased when Dinoprostone is combined with Imatinib.]
[C05CA03, diosmin, The metabolism of Imatinib can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Imatinib.]
[R06AA02, diphenhydramine, The serum concentration of Diphenhydramine can be increased when it is combined with Imatinib.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Imatinib.]
[B01AC07, dipyridamole, Imatinib may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Imatinib.]
[A03FA02, cisapride, The metabolism of Imatinib can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be increased when it is combined with Imatinib.]
[N05AL04, remoxipride, The serum concentration of Remoxipride can be increased when it is combined with Imatinib.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Imatinib.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Natalizumab.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Imatinib.]
[S02AA12, rifamycin SV, The metabolism of Imatinib can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Imatinib can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Imatinib may decrease the excretion rate of Riluzole which could result in a higher serum level.]
[N05AX08, risperidone, The serum concentration of Risperidone can be increased when it is combined with Imatinib.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Imatinib.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Imatinib.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Imatinib.]
[L01EX01, sunitinib, The serum concentration of Sunitinib can be increased when it is combined with Imatinib.]
[A04AD12, aprepitant, The metabolism of Imatinib can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Imatinib.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Imatinib.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be decreased when combined with Imatinib.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Imatinib.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Imatinib.]
[C01EB18, ranolazine, The serum concentration of Imatinib can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Imatinib can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Imatinib.]
[A03FA03, domperidone, The serum concentration of Domperidone can be increased when it is combined with Imatinib.]
[C01CA04, dopamine, The serum concentration of Dopamine can be increased when it is combined with Imatinib.]
[N06AA16, dothiepin, The serum concentration of Dosulepin can be increased when it is combined with Imatinib.]
[N06AA12, doxepin, The serum concentration of Doxepin can be increased when it is combined with Imatinib.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Imatinib.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Imatinib.]
[N06AB06, sertraline, The serum concentration of Sertraline can be increased when it is combined with Imatinib.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Imatinib.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Imatinib.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be increased when it is combined with Imatinib.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Imatinib.]
[N02CC01, sumatriptan, Imatinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[G01AF05, econazole, The serum concentration of Imatinib can be increased when it is combined with Econazole.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Imatinib.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Imatinib is combined with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Imatinib is combined with Temozolomide.]
[M01AC02, tenoxicam, The metabolism of Tenoxicam can be decreased when combined with Imatinib.]
[D01BA02, terbinafine, The metabolism of Imatinib can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Terodiline.]
[C07AA16, tertatolol, The serum concentration of Tertatolol can be increased when it is combined with Imatinib.]
[N06AX14, tianeptine, The serum concentration of Tianeptine can be increased when it is combined with Imatinib.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Imatinib.]
[N03AX11, topiramate, The metabolism of Imatinib can be decreased when combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Toremifene is combined with Imatinib.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Imatinib.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Triflusal is combined with Imatinib.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Imatinib is combined with Trilostane.]
[G03GA05, follitropin alfa, The therapeutic efficacy of Follitropin can be decreased when used in combination with Imatinib.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Imatinib.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Imatinib is combined with Trofosfamide.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Troxerutin is combined with Imatinib.]
[J01MA04, enoxacin, The metabolism of Imatinib can be decreased when combined with Enoxacin.]
[L01CA04, vinorelbine, The serum concentration of Vinorelbine can be increased when it is combined with Imatinib.]
[S01GX10, epinastine, The serum concentration of Epinastine can be increased when it is combined with Imatinib.]
[N06AX16, venlafaxine, The serum concentration of Venlafaxine can be increased when it is combined with Imatinib.]
[C08CA12, mepirodipine, The metabolism of Imatinib can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The serum concentration of Epinephrine can be increased when it is combined with Imatinib.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Imatinib.]
[N05CF02, zolpidem, The serum concentration of Zolpidem can be increased when it is combined with Imatinib.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Imatinib.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Imatinib.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Imatinib.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Anistreplase is combined with Imatinib.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Imatinib is combined with Carboplatin.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Imatinib.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Iloprost is combined with Imatinib.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Imatinib.]
[N02CA02, ergotamine, The serum concentration of Imatinib can be increased when it is combined with Ergotamine.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Imatinib.]
[N05CD04, estazolam, The serum concentration of Estazolam can be increased when it is combined with Imatinib.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Imatinib can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Imatinib.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Imatinib is combined with Estramustine.]
[G03CA57, estrogens, conjugated (USP), Imatinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, The metabolism of Imatinib can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Imatinib is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Imatinib is combined with Fluticasone.]
[C10AA04, fluvastatin, The serum concentration of Fluvastatin can be increased when it is combined with Imatinib.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Imatinib.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Imatinib.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Meloxicam.]
[S01XA06, ethylmorphine, The serum concentration of Ethylmorphine can be increased when it is combined with Imatinib.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Etidocaine.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Imatinib.]
[N05AE03, sertindole, The serum concentration of Sertindole can be increased when it is combined with Imatinib.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Imatinib.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Imatinib.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Imatinib.]
[R06AX11, astemizole, The serum concentration of Astemizole can be increased when it is combined with Imatinib.]
[R06AX12, terfenadine, The serum concentration of Imatinib can be increased when it is combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Imatinib can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The serum concentration of Fluvoxamine can be increased when it is combined with Imatinib.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Imatinib.]
[C01BC08, encainide, The serum concentration of Encainide can be increased when it is combined with Imatinib.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Imatinib.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Imatinib.]
[C10AA03, pravastatin, Pravastatin may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Imatinib which could result in a lower serum level and potentially a reduction in efficacy.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Dextran is combined with Imatinib.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Imatinib.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Imatinib.]
[P02CA03, albendazole, The metabolism of Imatinib can be increased when combined with Albendazole.]
[C08CA02, felodipine, The serum concentration of Felodipine can be increased when it is combined with Imatinib.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Imatinib.]
[N03AX26, fenfluramine, The serum concentration of Fenfluramine can be increased when it is combined with Imatinib.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Imatinib.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Imatinib.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Fibrinolysin is combined with Imatinib.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Imatinib is combined with Clofarabine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Imatinib.]
[N07AX03, cevimeline, The serum concentration of Cevimeline can be increased when it is combined with Imatinib.]
[C01BC04, flecainide, The serum concentration of Flecainide can be increased when it is combined with Imatinib.]
[J01CF05, floxacillin, Flucloxacillin may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[J02AC01, fluconazole, The metabolism of Imatinib can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Imatinib is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Imatinib is combined with Fludrocortisone.]
[N07CA03, flunarizine, The serum concentration of Flunarizine can be increased when it is combined with Imatinib.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Imatinib.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Imatinib is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Imatinib is combined with Fluocortolone.]
[V03AZ01, ethanol, The metabolism of Imatinib can be decreased when combined with Ethanol.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Imatinib.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Imatinib.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Imatinib.]
[N06AB03, fluoxetine, The serum concentration of Imatinib can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Flupentixol.]
[N05AB02, fluphenazine, The metabolism of Imatinib can be decreased when combined with Fluphenazine.]
[S01BC04, flurbiprofen, The metabolism of Flurbiprofen can be decreased when combined with Imatinib.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Imatinib.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Imatinib.]
[V04CX02, folic acid, Imatinib may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Imatinib.]
[J05AE10, darunavir, The serum concentration of Imatinib can be increased when it is combined with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Imatinib.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Imatinib.]
[N06DA04, galantamine, The serum concentration of Galantamine can be increased when it is combined with Imatinib.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Imatinib.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Ganciclovir is combined with Imatinib.]
[C10AB04, gemfibrozil, The metabolism of Imatinib can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Imatinib.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Imatinib.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Imatinib.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Imatinib.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Imatinib.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Imatinib.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Imatinib.]
[N01AH02, alfentanil, The metabolism of Alfentanil can be decreased when combined with Imatinib.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Imatinib.]
[A10BB01, glyburide, Glyburide may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Imatinib.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Imatinib.]
[N05CM18, dexmedetomidine, The metabolism of Imatinib can be decreased when combined with Dexmedetomidine.]
[C01BD04, dofetilide, The serum concentration of Dofetilide can be increased when it is combined with Imatinib.]
[C02CA04, doxazosin, The serum concentration of Doxazosin can be increased when it is combined with Imatinib.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Imatinib.]
[L01EX02, sorafenib, The serum concentration of Sorafenib can be increased when it is combined with Imatinib.]
[C07AB09, esmolol, The serum concentration of Esmolol can be increased when it is combined with Imatinib.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Imatinib.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Imatinib.]
[P01BX01, halofantrine, The metabolism of Imatinib can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Haloperidol.]
[N01AB01, halothane, The metabolism of Halothane can be decreased when combined with Imatinib.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Imatinib.]
[N05AH04, quetiapine, The serum concentration of Quetiapine can be increased when it is combined with Imatinib.]
[L01CE02, irinotecan, The serum concentration of Irinotecan can be increased when it is combined with Imatinib.]
[M04AA01, allopurinol, The risk or severity of adverse effects can be increased when Allopurinol is combined with Imatinib.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Imatinib.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Heparin is combined with Imatinib.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Imatinib.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Imatinib.]
[N05CA16, hexobarbital, The metabolism of Hexobarbital can be decreased when combined with Imatinib.]
[J05AG01, nevirapine, The serum concentration of Nevirapine can be increased when it is combined with Imatinib.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Imatinib.]
[M02AA26, nimesulide, The risk or severity of bleeding can be increased when Nimesulide is combined with Imatinib.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Imatinib.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Imatinib.]
[R05DA03, hydrocodone, The serum concentration of Hydrocodone can be increased when it is combined with Imatinib.]
[S02BA01, hydrocortisone, The metabolism of Hydrocortisone can be decreased when combined with Imatinib.]
[C03AA02, hydroflumethiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Imatinib.]
[P01BA02, hydroxychloroquine, The serum concentration of Hydroxychloroquine can be increased when it is combined with Imatinib.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Imatinib is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Imatinib can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The serum concentration of Imatinib can be decreased when it is combined with Ibuprofen.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Sodium citrate is combined with Imatinib.]
[L01DB06, idarubicin, The serum concentration of Idarubicin can be increased when it is combined with Imatinib.]
[L01AA06, ifosfamide, The serum concentration of Ifosfamide can be increased when it is combined with Imatinib.]
[H01AC02, somatrem, The metabolism of Imatinib can be increased when combined with Somatrem.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Imatinib.]
[L01CD01, paclitaxel, The serum concentration of Paclitaxel can be increased when it is combined with Imatinib.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Imatinib.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Imatinib is combined with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Imatinib.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Imatinib is combined with Topotecan.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Imatinib.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Imatinib.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Imatinib.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Imatinib.]
[N06AX17, milnacipran, The metabolism of Imatinib can be decreased when combined with Milnacipran.]
[S01XA28, varenicline, The excretion of Varenicline can be decreased when combined with Imatinib.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Articaine.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Imatinib.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Imatinib.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Imatinib.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Imatinib.]
[C10AA06, cerivastatin, Imatinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Imatinib.]
[C07AA01, alprenolol, The serum concentration of Alprenolol can be increased when it is combined with Imatinib.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Imatinib.]
[V03AB01, ipecac, The serum concentration of Ipecac can be increased when it is combined with Imatinib.]
[N06AF05, iproniazid, The metabolism of Imatinib can be decreased when combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Imatinib can be decreased when combined with Penciclovir.]
[P01AX06, atovaquone, The metabolism of Imatinib can be decreased when combined with Atovaquone.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Imatinib.]
[N04BX02, entacapone, The metabolism of Imatinib can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Imatinib can be decreased when combined with Isoniazid.]
[P02CF01, ivermectin, Imatinib may decrease the excretion rate of Ivermectin which could result in a higher serum level.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Bivalirudin is combined with Imatinib.]
[N06AX18, reboxetine, The metabolism of Imatinib can be decreased when combined with Reboxetine.]
[H01AC01, somatropin, The metabolism of Imatinib can be increased when combined with Somatotropin.]
[A02AB01, aluminum hydroxide, The absorption of Imatinib can be decreased when combined with Aluminum hydroxide.]
[L04AC07, tocilizumab, The metabolism of Imatinib can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Imatinib.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Ketanserin is combined with Imatinib.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Imatinib.]
[J02AB02, ketoconazole, The serum concentration of Imatinib can be increased when it is combined with Ketoconazole.]
[N05AH03, olanzapine, The serum concentration of Olanzapine can be increased when it is combined with Imatinib.]
[M02AA10, ketoprofen, The metabolism of Imatinib can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The serum concentration of Imatinib can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Imatinib can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Imatinib.]
[N04BC09, rotigotine, The serum concentration of Rotigotine can be increased when it is combined with Imatinib.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Imatinib.]
[C07AG01, labetalol, The serum concentration of Labetalol can be increased when it is combined with Imatinib.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Imatinib.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Imatinib.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Imatinib.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be decreased when combined with Imatinib.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be increased when it is combined with Imatinib.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Imatinib.]
[N06BA13, armodafinil, The metabolism of Imatinib can be decreased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Imatinib.]
[N02CA07, lisuride, The serum concentration of Lisuride can be increased when it is combined with Imatinib.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Imatinib is combined with Lomustine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Imatinib.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Imatinib.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Imatinib.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be increased when it is combined with Imatinib.]
[G04BX01, magnesium hydroxide, The absorption of Imatinib can be decreased when combined with Magnesium hydroxide.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Imatinib is combined with Pralatrexate.]
[L01EA03, nilotinib, The serum concentration of Imatinib can be increased when it is combined with Nilotinib.]
[N06AA21, maprotiline, The serum concentration of Maprotiline can be increased when it is combined with Imatinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Imatinib is combined with Mechlorethamine.]
[R06AE05, meclizine, The serum concentration of Meclizine can be increased when it is combined with Imatinib.]
[C01AA08, medigoxin, Metildigoxin may decrease the cardiotoxic activities of Imatinib.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Imatinib.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Nadroparin is combined with Imatinib.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Enoxaparin is combined with Imatinib.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Dalteparin is combined with Imatinib.]
[N05CH01, melatonin, The metabolism of Melatonin can be decreased when combined with Imatinib.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Imatinib is combined with Melphalan.]
[N06DX01, memantine, The serum concentration of Memantine can be increased when it is combined with Imatinib.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Imatinib.]
[N03AB04, mephenytoin, The serum concentration of Mephenytoin can be increased when it is combined with Imatinib.]
[N03AA01, mephobarbital, The metabolism of Methylphenobarbital can be decreased when combined with Imatinib.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Mepivacaine.]
[N05AC03, mesoridazine, The serum concentration of Mesoridazine can be increased when it is combined with Imatinib.]
[N05AX13, paliperidone, The serum concentration of Paliperidone can be increased when it is combined with Imatinib.]
[A10BA02, metformin, The serum concentration of Metformin can be increased when it is combined with Imatinib.]
[A04AA04, dolasetron, The serum concentration of Dolasetron can be increased when it is combined with Imatinib.]
[N07BC02, methadone, The serum concentration of Methadone can be increased when it is combined with Imatinib.]
[N06BA03, methamphetamine, The serum concentration of Metamfetamine can be increased when it is combined with Imatinib.]
[J05AF05, lamivudine, Imatinib may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[H03BB02, methimazole, The serum concentration of Imatinib can be increased when it is combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Imatinib is combined with Pemetrexed.]
[L04AX03, methotrexate, The serum concentration of Methotrexate can be increased when it is combined with Imatinib.]
[N05AA02, methotrimeprazine, The serum concentration of Methotrimeprazine can be increased when it is combined with Imatinib.]
[D05BA02, methoxsalen, The metabolism of Imatinib can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The serum concentration of Methoxyflurane can be increased when it is combined with Imatinib.]
[C03AA08, methyclothiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Imatinib.]
[V04CG05, methylene blue, The serum concentration of Methylene blue can be increased when it is combined with Imatinib.]
[R03DA05, aminophylline, The serum concentration of Aminophylline can be increased when it is combined with Imatinib.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Imatinib is combined with Methylprednisolone.]
[N02CA04, methysergide, The metabolism of Methysergide can be decreased when combined with Imatinib.]
[A03FA01, metoclopramide, The serum concentration of Metoclopramide can be increased when it is combined with Imatinib.]
[C07AB02, metoprolol, The serum concentration of Metoprolol can be increased when it is combined with Imatinib.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Imatinib.]
[C01BB02, mexiletine, The serum concentration of Mexiletine can be increased when it is combined with Imatinib.]
[N06AX03, mianserin, The serum concentration of Mianserin can be increased when it is combined with Imatinib.]
[S02AA13, miconazole, The metabolism of Imatinib can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The serum concentration of Aminophenazone can be increased when it is combined with Imatinib.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Parnaparin is combined with Imatinib.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Imatinib.]
[G03XB01, mifepristone, The serum concentration of Imatinib can be increased when it is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Tinzaparin is combined with Imatinib.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Imatinib.]
[L01XX23, mitotane, The metabolism of Imatinib can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Imatinib is combined with Mitoxantrone.]
[N06BA12, lisdexamfetamine, The serum concentration of Lisdexamfetamine can be increased when it is combined with Imatinib.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Imatinib.]
[C01BD01, amiodarone, The serum concentration of Imatinib can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Imatinib.]
[N02AA01, morphine, The metabolism of Imatinib can be decreased when combined with Morphine.]
[A04AA05, palonosetron, The serum concentration of Palonosetron can be increased when it is combined with Imatinib.]
[L04AB05, certolizumab pegol, The metabolism of Imatinib can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Imatinib can be decreased when combined with Eltrombopag.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Ofatumumab.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Imatinib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Imatinib is combined with Mycophenolic acid.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Imatinib.]
[G03XC01, raloxifene, Imatinib may decrease the excretion rate of Raloxifene which could result in a higher serum level.]
[N06AA17, amoxapine, The serum concentration of Amoxapine can be increased when it is combined with Imatinib.]
[N03AB05, fosphenytoin, The metabolism of Imatinib can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Imatinib.]
[C07AA12, nadolol, The serum concentration of Nadolol can be increased when it is combined with Imatinib.]
[J01CF06, nafcillin, The metabolism of Imatinib can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The serum concentration of Imatinib can be increased when it is combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Imatinib can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The serum concentration of Amphetamine can be increased when it is combined with Imatinib.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Imatinib.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[N06AX21, duloxetine, The serum concentration of Duloxetine can be increased when it is combined with Imatinib.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Imatinib.]
[L01CD02, docetaxel, The serum concentration of Docetaxel can be increased when it is combined with Imatinib.]
[L02BG04, letrozole, The metabolism of Imatinib can be decreased when combined with Letrozole.]
[A10BX02, repaglinide, Imatinib may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Imatinib.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Tirofiban is combined with Imatinib.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Imatinib.]
[N06AX23, desvenlafaxine, The metabolism of Imatinib can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Telmisartan may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[M04AA03, febuxostat, The excretion of Imatinib can be decreased when combined with Febuxostat.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Imatinib.]
[C10AD02, niacin, The metabolism of Imatinib can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The serum concentration of Nicardipine can be increased when it is combined with Imatinib.]
[C04AE02, nicergoline, The serum concentration of Nicergoline can be increased when it is combined with Imatinib.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Imatinib.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Nicotine is combined with Imatinib.]
[C08CA05, nifedipine, The serum concentration of Nifedipine can be increased when it is combined with Imatinib.]
[C08CA06, nimodipine, The serum concentration of Nimodipine can be increased when it is combined with Imatinib.]
[C08CA07, nisoldipine, The serum concentration of Nisoldipine can be increased when it is combined with Imatinib.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Imatinib.]
[J01XE01, nitrofurantoin, Imatinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be decreased when combined with Imatinib.]
[N04BC05, pramipexole, The serum concentration of Pramipexole can be increased when it is combined with Imatinib.]
[C01CA03, norepinephrine, The serum concentration of Norepinephrine can be increased when it is combined with Imatinib.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Imatinib.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Imatinib.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Imatinib.]
[R05DA07, noscapine, The metabolism of Imatinib can be decreased when combined with Noscapine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Eptifibatide is combined with Imatinib.]
[L03AB07, interferon beta-1a, The metabolism of Imatinib can be decreased when combined with Interferon beta-1a.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Reviparin is combined with Imatinib.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Imatinib.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Imatinib.]
[L04AC04, rilonacept, The metabolism of Imatinib can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Imatinib.]
[N02AA02, opium, The serum concentration of Opium can be increased when it is combined with Imatinib.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Reteplase is combined with Imatinib.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Ancrod is combined with Imatinib.]
[G04CA02, tamsulosin, The serum concentration of Tamsulosin can be increased when it is combined with Imatinib.]
[C01AC01, ouabain, Ouabain may decrease the cardiotoxic activities of Imatinib.]
[P02BA02, oxamniquine, The metabolism of Imatinib can be decreased when combined with Oxamniquine.]
[A14AA08, oxandrolone, The metabolism of Imatinib can be decreased when combined with Oxandrolone.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Imatinib.]
[C07AA02, oxprenolol, The serum concentration of Oxprenolol can be increased when it is combined with Imatinib.]
[N02AA05, oxycodone, The serum concentration of Oxycodone can be increased when it is combined with Imatinib.]
[N02AA11, oxymorphone, The serum concentration of Oxymorphone can be increased when it is combined with Imatinib.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Imatinib.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Imatinib is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Danaparoid is combined with Imatinib.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Imatinib.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Imatinib.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Imatinib is combined with Paramethasone.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Imatinib.]
[G04BD11, fesoterodine, The serum concentration of Fesoterodine can be increased when it is combined with Imatinib.]
[C07AA23, penbutolol, The serum concentration of Penbutolol can be increased when it is combined with Imatinib.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Imatinib.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Imatinib is combined with Penicillamine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Imatinib.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Imatinib.]
[N05CA01, pentobarbital, The metabolism of Imatinib can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Imatinib.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be decreased when combined with Imatinib.]
[C08EX02, perhexiline, The serum concentration of Perhexiline can be increased when it is combined with Imatinib.]
[N05AB03, perphenazine, The serum concentration of Perphenazine can be increased when it is combined with Imatinib.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Imatinib.]
[N02BE03, phenacetin, The serum concentration of Phenacetin can be increased when it is combined with Imatinib.]
[A10BA01, phenformin, The serum concentration of Phenformin can be increased when it is combined with Imatinib.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Phenindione is combined with Imatinib.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Imatinib.]
[N03AA02, phenobarbital, The metabolism of Imatinib can be increased when combined with Phenobarbital.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Imatinib.]
[B01AA04, phenprocoumon, The serum concentration of Phenprocoumon can be increased when it is combined with Imatinib.]
[M02AA01, phenylbutazone, The metabolism of Phenylbutazone can be decreased when combined with Imatinib.]
[S01GA05, phenylephrine, The metabolism of Imatinib can be increased when combined with Phenylephrine.]
[A02BC06, dexlansoprazole, The metabolism of Imatinib can be decreased when combined with Dexlansoprazole.]
[N03AB02, phenytoin, The metabolism of Imatinib can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Imatinib can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Imatinib.]
[L02BB03, bicalutamide, The serum concentration of Bicalutamide can be increased when it is combined with Imatinib.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Imatinib.]
[N05AG02, pimozide, The serum concentration of Pimozide can be increased when it is combined with Imatinib.]
[C07AA03, pindolol, The serum concentration of Pindolol can be increased when it is combined with Imatinib.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Imatinib.]
[J05AE01, saquinavir, The serum concentration of Imatinib can be increased when it is combined with Saquinavir.]
[P02CB01, piperazine, The serum concentration of Piperazine can be increased when it is combined with Imatinib.]
[N05AC04, pipothiazine, The serum concentration of Pipotiazine can be increased when it is combined with Imatinib.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Imatinib.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Imatinib.]
[J05AG02, delavirdine, The serum concentration of Imatinib can be increased when it is combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Imatinib.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Abciximab is combined with Imatinib.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Imatinib.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Alteplase is combined with Imatinib.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Imatinib.]
[L02BG03, anastrozole, The risk or severity of cardiotoxicity can be increased when Imatinib is combined with Anastrozole.]
[A03AE01, alosetron, The metabolism of Imatinib can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Imatinib can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Imatinib.]
[J05AE03, ritonavir, The serum concentration of Imatinib can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Imatinib.]
[V03AB21, potassium iodide, The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Imatinib.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Imatinib.]
[C07AB01, practolol, The serum concentration of Practolol can be increased when it is combined with Imatinib.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Imatinib.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Imatinib.]
[C02CA01, prazosin, Imatinib may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Imatinib is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Imatinib is combined with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Imatinib.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Imatinib.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Imatinib can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Imatinib can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Imatinib can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Imatinib.]
[C01BA02, procainamide, The serum concentration of Procainamide can be increased when it is combined with Imatinib.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Imatinib is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Imatinib is combined with Procarbazine.]
[C10AB05, fenofibrate, Imatinib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The serum concentration of Prochlorperazine can be increased when it is combined with Imatinib.]
[G03DA04, progesterone, The serum concentration of Progesterone can be increased when it is combined with Imatinib.]
[N05AA03, promazine, The serum concentration of Promazine can be increased when it is combined with Imatinib.]
[R06AD02, promethazine, The serum concentration of Promethazine can be increased when it is combined with Imatinib.]
[C01BC03, propafenone, The serum concentration of Propafenone can be increased when it is combined with Imatinib.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Imatinib.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Imatinib.]
[N02AC04, propoxyphene, The serum concentration of Dextropropoxyphene can be increased when it is combined with Imatinib.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Imatinib.]
[H03BA02, propylthiouracil, The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Imatinib.]
[C01AB01, proscillaridin, Proscillaridin may decrease the cardiotoxic activities of Imatinib.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Epoprostenol is combined with Imatinib.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Imatinib.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Imatinib.]
[N05AX12, aripiprazole, The serum concentration of Aripiprazole can be increased when it is combined with Imatinib.]
[N07XX07, dalfampridine, The serum concentration of Dalfampridine can be increased when it is combined with Imatinib.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Imatinib.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Imatinib.]
[P01BD01, pyrimethamine, The metabolism of Imatinib can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Imatinib.]
[C01BA01, quinidine, The serum concentration of Quinidine can be increased when it is combined with Imatinib.]
[P01BC01, quinine, The serum concentration of Quinine can be increased when it is combined with Imatinib.]
[A02BA02, ranitidine, The serum concentration of Ranitidine can be increased when it is combined with Imatinib.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[J04AB02, rifampin, The serum concentration of Imatinib can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Imatinib.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Imatinib is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Imatinib.]
[N05CA06, secobarbital, The metabolism of Imatinib can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The serum concentration of Selegiline can be increased when it is combined with Imatinib.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Imatinib is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Imatinib.]
[C07AA07, sotalol, The serum concentration of Sotalol can be increased when it is combined with Imatinib.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Imatinib.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Imatinib.]
[C03DA01, spironolactone, The metabolism of Imatinib can be decreased when combined with Spironolactone.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Imatinib.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Imatinib is combined with Hydrocortisone butyrate.]
[L01CD03, paclitaxel poliglumex, The risk or severity of cardiotoxicity can be increased when Imatinib is combined with Paclitaxel poliglumex.]
[H02CA04, levoketoconazole, The serum concentration of Imatinib can be increased when it is combined with Levoketoconazole.]
[A05AA02, ursodiol, Ursodeoxycholic acid may decrease the excretion rate of Imatinib which could result in a higher serum level.]
